Management and Personnel
Michael Fitzgerald - ChairmanMichael is the founder of the Cloverleaf Group and is primarily focused on sourcing new investment opportunities as well as chairing many of the Cloverleaf Group’s existing investments, particularly those based in Europe. Michael also specialises in the structuring and financing of innovative technology and healthcare companies and in the provision of international banking and corporate legal services to clients in Australia, the United States and the United Kingdom.
In 1995, Michael co-founded Gemini Genomics plc (Nasdaq: GMNI) and from 1995 to 2001 he served as Chairman and representative of the lead shareholder. Gemini was successfully merged with Sequenom, Inc. (Nasdaq: SQNM) in September 2001 in a transaction which valued Gemini at $238 million.
Most recently, Michael co-founded and acts or acted as Chairman of each of Block Shield Corporation plc, Medcenter Holdings, Inc., Quadrant Technologies Limited and Zenergy Power plc and is a director of Clear Play International, Inc. and Roxro Pharma, Inc.
Michael has a Masters in Law and is admitted as a barrister in England and Wales, a barrister and solicitor in Victoria, Australia and a solicitor in New South Wales, Australia. He has authored numerous papers on company and banking law. David Whelan - Chief Executive
David Whelan joined the Cloverleaf Group as Chief Executive in April 2006. David is primarily focused on managing the Cloverleaf Group’s existing investments, particularly those based in the Americas, as well as sourcing new investment opportunities.
David is a director of the following Cloverleaf Group portfolio companies: AgaMatrix, Inc; Block Shield Corporation Plc; Clear Play International, Inc; MD Datacor, Inc. and Medcenter Holdings, Inc.
Prior to joining the Cloverleaf Group, David was Vice President of Corporate Development with the Virgin Group in the US and the UK. David was previously an investment banker in London, England and Sydney, Australia with Goldman Sachs & Company and before that Deutsche Bank. Starting his career at Price Waterhouse in the firm’s Corporate Finance division in Sydney, Australia, David is also a Chartered Accountant of Australia.
David has a Bachelor of Laws (Honours) and Bachelor of Commerce from Bond University in Queensland, Australia. Vinay Kolla - Principal
Vinay Kolla joined the Cloverleaf Group as an Associate in March 2008. Vinay is primarily engaged in assisting in the management of Cloverleaf Group’s existing investments as well as the development and sourcing of new investment opportunities.
Most recently, Vinay was an Associate and founding member of the US equity capital markets group of HSBC and an Associate in credit sales at Barclays Capital. Prior to this Vinay was an Analyst in mergers and acquisitions and corporate finance at Lazard Freres & Co. While at Lazard, Vinay focused on technology, media, telecommunications mergers and acquisitions and life sciences equity capital markets.
Vinay holds a Bachelor of Science from Duke University and a Masters of Business Administration from Columbia Business School. Vinay also received a General Course Certificate from the London School of Economics and Political Science.